Research To Practice | Oncology Videos

Featuring an interview with Drs Jeffrey Bradley and David Spigel, including the following topics: Clinical Investigator Perspectives on the Management of Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (0:00) Multimodality Management Options for Patients with Unresectable Stage III NSCLC — Jeffrey Bradley, MD (35:46) Integration of Immune Checkpoint Inhibition into the Management of Unresectable Stage III NSCLC — David R Spigel, MD (1:03:41) Case presentations by Dr Bradley (1:25:27) Case Presentations by Dr Spigel (1:37:44) CME information and select publications

Featuring perspectives from Prof Ghassan Abou-Alfa, including the following topics: Introduction (0:00) Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Syed M Ahmed, MD, PhD (2:56) Key recent data sets (5:59) Case: A man in his mid 60s with a history of Child-Pugh B cirrhosis and Grade 1 esophageal varices who is receiving atezolizumab/bevacizumab for multifocal HCC — Raji Shameem, MD (22:28) Case: A man in his late 60s with previously treated HCC cirrhosis who is now diagnosed with potentially resectable HCC — Syed F Zafar, MD (29:30) Case: A woman in her late 70s receiving adjuvant anastrozole for Stage I breast cancer who is now receiving atezolizumab/bevacizumab for metastatic HCC — Sunil Gandhi, MD (33:41) Case: A man in his late 70s with metastatic HCC and portal vein thrombosis receiving atezolizumab/bevacizumab (NGS [next-generation sequencing] with PIK3CA mutation, PD-L1 50%) — Susmitha Apuri, MD (35:47) Management of Biliary Tract Cancers (40:18) Case: A man in his late 50s with resected Stage IIB gallbladder cancer s/p adjuvant capecitabine who now has metastatic disease (HER2-positive; MSS, PD-L10) — Nasfat Shehadeh, MD (44:01) Case: A woman in her early 40s with a history of ductal carcinoma in situ and family history of breast cancer, now with metastatic cholangiocarcinoma (NGS with IDH2 mutation) — Joanna Metzner-Sadurski, MD (53:41) CME information and select publications

Featuring a slide presentation and related discussion from Dr Sandy Srinivas, including the following topics: Results from the Phase II SALV-ENZA trial evaluating salvage radiation therapy with enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy (0:00) Updated overall survival outcomes from the ENZAMET trial of enzalutamide for metastatic hormone-sensitive prostate cancer (3:48) Genomic alterations associated with overall survival for patients with metastatic castration-sensitive prostate cancer treated with apalutamide or placebo with androgen deprivation therapy in the TITAN study (7:43) Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel (9:56) Further results from the Phase III PROpel trial of abiraterone with olaparib for patients with metastatic castration-resistant prostate cancer (12:32) Results from the MAGNITUDE study of niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (15:39) The role of perioperative chemoimmunotherapy in muscle-invasive urothelial carcinoma (18:23) Long-term outcomes from the Phase III EV-301 trial: Enfortumab vedotin versus chemotherapy for patients with previously treated advanced urothelial carcinoma (21:44) First results from trials of the novel anti-HER2 antibody-drug conjugate RC48 alone and in combination with the anti-PD-1 antibody toripalimab; results from cohorts 3, 4 and 5 of the COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab for urothelial carcinoma (23:12) Updated analyses of exploratory endpoints from the KEYNOTE-564 and CheckMate 9ER trials in renal cell carcinoma (RCC) (26:37) Updates on tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy and other novel approaches for patients with RCC (29:08) CME information and select publications

Featuring an interview with Dr Sandy Srinivas, including the following topics: Rationale for and efficacy data from the Phase II SALV-ENZA trial of salvage radiation therapy with enzalutamide or placebo for high-risk recurrent hormone-sensitive prostate cancer (0:00) Results from clinical trials evaluating abiraterone, docetaxel or apalutamide for patients with hormone-sensitive prostate cancer (3:29) TheraP trial: Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic hormone-resistant prostate cancer (8:31) Clinical data with abiraterone acetate in combination with PARP inhibition for patients with metastatic hormone-resistant prostate cancer: Results from the PROpel and MAGNITUDE trials (13:54) Current role of neoadjuvant chemotherapy with immunotherapy for patients with metastatic urothelial bladder cancer (UBC); updated long-term outcomes with enfortumab vedotin from the EV-301 trial (20:23) Clinical pearls for preventing and managing adverse events with erdafitinib, sacituzumab govitecan or enfortumab vedotin in patients with UBC (25:23) HER2 expression in UBC and emerging data with the novel HER2-targeted antibody-drug conjugate RC48 alone and in combination with toripalimab; tolerability of antibody-drug conjugates (30:53) Follow-up efficacy and safety data from the KEYNOTE-564 trial; practical implications of the safety data with adjuvant pembrolizumab for renal cell carcinoma (RCC) (36:16) Emerging data with the novel agent belzutifan for advanced clear cell RCC (40:11) Current practice and potential advances in the first-line treatment of metastatic RCC (44:25) CME information and select publications

Featuring perspectives from Dr Richard Stone, including the following topics: Introduction: RATIFY trial in perspective (0:00) Treatment with FLT3 inhibitors (7:00) Anti-CD47 antibody: Magrolimab (23:04) Anti-TIM-3 antibody: Sabatolimab (31:23) CAR T-cell therapy for acute myeloid leukemia (34:53) Targeted therapy with IDH inhibitors (37:31) New myelodysplastic syndromes classification system (41:20) Hypomethylating agents/venetoclax (45:11) CPX-351 (49:14) Other key data sets (50:59) CME information and select publications

Featuring perspectives from Dr Christopher Flowers and Ms Robin Klebig, including the following topics: Management of Diffuse Large B-Cell Lymphoma (0:00) Caring for Patients with Hodgkin Lymphoma (32:59) Treatment for Follicular Lymphoma (44:17) Managing Mantle Cell Lymphoma (58:12) NCPD information and select publications

Featuring a slide presentation and related discussion from Professor Juan Valle, including the following topics: Management of biliary tract cancers (BTCs) with targetable mutations (0:00) Management of BTCs without targetable mutations (13:59) Novel targets and treatments for cholangiocarcinoma and other BTCs (20:19) CME information and select publications

Featuring an interview with Professor Juan Valle, including the following topics: Immunotherapy for patients with biliary tract cancers (BTCs) (0:00) Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18) Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47) Spectrum and management of toxicities associated with FGFR inhibitors (19:33) Targeting driver mutations beyond FGFR (28:16) Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53) Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49) Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15) CME information and select publications

Featuring perspectives from Dr Jorge Cortes, including the following topics: Introduction: Journal Club with Dr Cortes (0:00) Case: A man in his early 40s with chronic myeloid leukemia (CML) and osteopenia after long-term imatinib therapy — Rajalaxmi McKenna, MD (15:00) Case: A man in his early 60s with chronic phase CML (CP-CML) and continued detectable BCR-ABL transcript on bosutinib — Bruce Bank, MD (23:55) Case: A man in his early 70s with CP-CML and notable toxicities from several BCR-ABL tyrosine kinase inhibitors (TKIs) — Gigi Chen, MD (27:37) Case: A woman in her late 40s with CML in complete molecular response for more than 3 years with nilotinib — Michael R Grunwald, MD (36:05) Case: A woman in her mid 60s with CP-CML and negative BCR-ABL mutational analyses who experiences lack of disease response to several BCR-ABL TKIs — Shams Bufalino, MD (43:27) Case: A man in his early 40s with CP-CML who is found to have a T315I mutation — Dr Grunwald (44:45) Appendix of Key Recent Data Sets (53:26) CME information and select publications

Featuring perspectives from Dr Joel Neal, including the following topics: Introduction: Journal Club with Joel W Neal, MD, PhD (0:00) Case: A woman in her mid 60s with Stage I NSCLC with an EGFR mutation and emphysema — Joanna Metzner-Sadurski, MD (18:00) Case: A woman in her late 60s with localized papillary NSCLC with an EGFR L864Q mutation — William R Mitchell, MD (20:42) Case: A woman in her early 70s with Stage IIIA NSCLC and EGFR L858R, ROS1 and TP53 mutations — Neil Morganstein, MD (37:25) Case: A woman in her early 50s with metastatic NSCLC with an EGFR exon 20 insertion (PD-L1 TPS 20%) — Julia Saylors, MD (43:11) Case: A woman in her early 70s with metastatic NSCLC with an EGFR exon 19 mutation (PD-L1 TPS 50%) — Namrata I Peswani, MD (53:53) CME information and select publications